Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ganetespib
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9090-14, NCI-2013-01034, NCT01798485
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN-064, NCI-2013-01416, 13-028, NCT01962948
A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SARC023, NCI-2014-02429, NCT02008877
Ganetespib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-048, NCI-2010-01920, NCT01173523
Ganetespib in Treating Patients with Stage IV Ocular Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-137, NCI-2010-02206, NCT01200238
Hsp90 inhibitor STA-9090 in Treating Patients With Metastatic or Advanced Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-145, NCI-2011-00085, NCT01273896
Hsp90 inhibitor STA-9090 With or Without Dutasteride in Treating Patients With Hormone-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-333, NCI-2011-00909, NCT01368003
Ganetespib in Treating Patients With Previously Treated Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-039, NCI-2011-03090, NCT01551693
Ganetespib with and without Bortezomib in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: WCI2005-11, NCI-2012-00190, IRB00049962, MMRC037, MMRC037/EIRB#49962, NCT01485835
Ganetespib, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with Advanced or Metastatic HER2+ Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S12-03732, NCI-2014-00177, NCT02060253
Ganetespib and Ziv-Aflibercept in Treating Patients with Refractory or Metastatic Gastrointestinal Cancer, Non-small Cell Lung Cancer, Urothelial Cancer, or Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: 14-C-0150, NCI-2014-00626, 09-25-0099, 141525, P141525, 9605, NCT02192541
Ganetespib in Combination with Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients with Stage II-III Esophageal Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0815, NCI-2015-00492, NCT02389751
Ganetespib before Surgery in Treating Patients with Stage I-IVA Squamous Cell Carcinoma of the Head and Neck That Can Be Removed by Surgery
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 to 79
Trial IDs: WINSHIP2572-13, NCI-2014-02605, NCT02334319
Start Over